Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Parag Jasani

Parag Jasani

FRCPath, MBBS, MRCP
Royal Free London NHS Foundation Trust
The key barrier to making the implementation of bispecific antibodies in CLL possible 0:41
The key barrier to making the implementation of bispecific antibodies in CLL possible
Parag Jasani • 14 Sep 2025
Investigating bispecific antibodies in CLL 1:00
Investigating bispecific antibodies in CLL
Parag Jasani • 14 Sep 2025
The potential of bispecific antibodies in CLL 1:04
The potential of bispecific antibodies in CLL
Parag Jasani • 14 Sep 2025
Personalizing CLL therapy in the frontline 0:56
Personalizing CLL therapy in the frontline
Parag Jasani • 10 Dec 2023
NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study 1:29
NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study
Parag Jasani • 10 Dec 2023
Phase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL 0:58
Phase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL
Parag Jasani • 10 Dec 2022
The current treatment landscape in CLL 0:56
The current treatment landscape in CLL
Parag Jasani • 10 Dec 2022
The evolution of treatment for elderly patients with CLL 0:44
The evolution of treatment for elderly patients with CLL
Parag Jasani • 10 Dec 2022
What to look forward to at ASCO 2022 0:43
What to look forward to at ASCO 2022
Parag Jasani • 30 May 2022
The rationale behind targeting ROR1 in CLL and MCL 1:37
The rationale behind targeting ROR1 in CLL and MCL
Parag Jasani • 30 May 2022
NVG-111: a ROR1-targeting bispecific T-cell engager for CLL and MCL 2:16
NVG-111: a ROR1-targeting bispecific T-cell engager for CLL and MCL
Parag Jasani • 30 May 2022
The content of VJHemOnc is intended for healthcare professionals